The role of insulin receptor substrate-1 in transformation by v-src

Journal of Cellular Physiology

Volumn 215, Issue 3, 2008, Pages 725-732

  Sun, Hongzhi ^a   Baserga, Renato ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; INSULIN RECEPTOR SUBSTRATE 1; PROTEIN TYROSINE KINASE; RIBOSOME DNA; STAT3 PROTEIN; INSULIN RECEPTOR SUBSTRATE 1 PROTEIN; INSULIN RECEPTOR SUBSTRATE-1 PROTEIN; MICRORNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE P60; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SMALL INTERFERING RNA;

ANIMAL CELL; ARTICLE; CELL CYCLE PROGRESSION; CELL TRANSFORMATION; CONTROLLED STUDY; CULTURE MEDIUM; DOWN REGULATION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN TRANSPORT; ANIMAL; BINDING SITE; CELL LINE; CELL PROLIFERATION; CHEMISTRY; CONFOCAL MICROSCOPY; GENETICS; HUMAN; METABOLISM; PROTEIN BINDING; PROTEIN TERTIARY STRUCTURE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; BINDING SITES; CELL LINE; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN D1; DNA, RIBOSOMAL; DOWN-REGULATION; HUMANS; MICE; MICRORNAS; MICROSCOPY, CONFOCAL; ONCOGENE PROTEIN PP60(V-SRC); PROMOTER REGIONS (GENETICS); PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS PP60(C-SRC); RNA, SMALL INTERFERING; STAT3 TRANSCRIPTION FACTOR;

EID: 42949130647     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.21352     Document Type: Article

References (51)

1. Aoki M, Schetter C, Himly M, Batista O, Chang HW, Vogt PK. 2000. The catalytic subunit of phosphatidylinositol 3-kinase: Requirements for oncogenicity. J Biol Chem 275:6267-6275.
2. Bader AG, Vogt PK. 2004. An essential role for protein synthesis in oncogenic cellular transformation. Oncogene 23:3145-3150.
3. Baserga R. 2005. The insulin-like growth factor-1 receptor as a target for cancer therapy. Expert Opin Ther Targets 9:753-768.
4. Baserga R, Peruzzi F, Reiss K. 2003. The IGF-1 receptor in cancer biology. Int J Cancer 107:873-877.
5. Bromberg J, Darnell JE, Jr. 2000. The role of STATs in transcriptional control and their impact on cellular function. Oncogene 19:2468-2473.
6. Bromberg JF, Horvath CM, Besser D, Lathem WW, Darnell JE. 1998. Stat 3 activation is required for cellular transformation by v-src. Mol Cell Biol 18:2553-2558.
7. Byron SA, Horwitz KB, Richer JK, Lange CA, Zhang X, Byron SA, Horwitz KB, Richer JK, Lange CA, Zhang X, Yee D. 2006. Insulin receptor substrates mediate distinct biological responses to insulin-like growth factor receptor activation in breast cancer cells. Br J Cancer 95:120-1228.
8. Castles GC, Fuqua SA, Klotz DM, Hill SM. 1993. Expression of a constitutively active estrogen receptor variant in the estrogen receptor-negative BT20 human breast cancer cell line. Cancer Res 53:5934-5939.
9. Cesarone G, Garofalo C, Abrams MT, Igoucheva O, Alexeev V, Yoon K, Surmacz E, Wickstrom E. 2006. RNAi-mediated silencing of insulin receptor substrate-1 (IRS-1) enhances tamoxifen-induced cell death in MCF-7 breast cancer cells. J Cell Biochem 98:440-450.
10. Chang Q, Li Y, White MF, Fletcher JA, Xiao S. 2002. Constitutive activation of insulin receptor substrate-1 is a frequent event in human tumors: Therapeutic implications. Cancer Res 62:6035-6038.
11. Chen J, Wu A, Sun H, Drakas R, Garofalo C, Cascio S, Surmacz E, Baserga R. 2005. Functional significance of type 1 insulin-like growth factor-mediated nuclear translocation of the insulin receptor substrate-1 and β-catenin. J Biol Chem 280:29912-29920.
12. Cristofanelli B, Valentinis B, Soddu S, Rizzo MG, Marchetti A, Bossi G, Morena AR, Dews M, Baserga R, Sacchi A. 2000. Co-operative transformation of 32D cells by the combined expression of IRS-1 and v-Ha-Ras. Oncogene 19:3245-3255.
13. Cui Q, Yu Z, Purisima EO, Wang E. 2006. Principles of microRNA regulation of a human cellular signaling network. Mol Systems Biol 2:46.
14. D'Ambrosio C, Keller SR, Morrione A, Lienhard GE, Baserga R, Surmacz E. 1995. Transforming potential of the insulin receptor substrate-1. Cell Growth Diff 6:557-562.
15. Dalmizrak O, Wu A, Chen J, Sun H, Utama FE, Zambelli D, Tran TH, Rui H, Baserga R. 2007. The insulin receptor substrate-1 regulates the transformed phenotype of BT-20 human mammary cancer cells. Cancer Res 67:2124-2130.
16. DeAngelis T, Chen J, Wu A, Prisco M, Baserga R. 2006. Transformation by the Simian Virus 40 T antigen is regulated by IGF-1 receptor and IRS-1 signaling. Oncogene 25:32-42.
17. Dearth RK, Cui X, Kim HJ, Kuiatse I, Lawrence NA, Zhang X, Divisova J, Britton OL, Mohsin S, Allred DC, Hadsell DL, Lee AV. 2006. Mammary tumorigenesis and metastasis caused by overexpression of the insulin receptor substrate-1 (IRS-1) or IRS-2. Mol Cell Biol 26:9302-9314.
18. Del Rincon SV, Guo Q, Morelli C, Shiu HY, Surmacz E, Miller WH. 2004. Retinole acid mediates degradation of IRS-1 by the ubiquitin-proteasome pathway, via a PKC-dependent mechanism. Oncogene 23:9269-9279.
19. Garcia R, Jove R. 1998. Activation of Stat transcription factors in oncogenic tyrosine kinase signaling. J Biomed Sci 5:79-85.
20. Kang S, Bader AG, Vogt PK. 2005. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci 102:802-807.
21. Klippel A, Escobedo MA, Wachowicz MS, Apell G, Brown TW, Giedlin MA, Kavanaugh WM, Williams LT. 1998. Activation of phosphatidylinositol 3-kinase is sufficient for cell cycle entry and promotes cellular changes characteristic of oncogenic transformation. Mol Cell Biol 18:5699-5711.
22. Kozma LM, Weber MJ. 1990. Constitutive phosphorylation of the receptor for the insulin-like growth factor 1 in cells transformed by the src oncogene. Mol Cell Biol 10:3626-3634.
23. Lannon CL, Martin MJ, Tognon CE, Jin W, Kim SJ, Sorensen PHB. 2004. A highly conserved NTRK3 C-terminal sequence in the ETV6-NTRK3 oncoprotein binds the phosphotyrosine binding domain of insulin receptor substrate-1. J Biol Chem 279:6225-6234.
24. Larsson O, Girnita A, Girnita L. 2007. Role of insulin-like growth factor receptor signaling in cancer. Br J Cancer 92:2097-2101.
25. Leslie K, Lang C, Devgan G, Azare J, Berishaj M, Gerald W, Kim YB, Paz K, Darnell JE, Albanese C, Sakamaki T, Pestell R, Bromberg J. 2006. Cyclin D1 is transcriptionally regulated by and required for transformation by activated signal transducer and activator of transcription 3. Cancer Res 66:2544-2552.
26. Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, Battel DP, Linsley PS, Johnson JM. 2005. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 433:769-773.
27. Liu J-P, Baker J, Perkins AS, Robertson EJ, Efstratiadis A. 1993. Mice carrying null mutations of the genes encoding insulin-like growth factor 1 (igf-1) and type 1 IGF receptor (Igf1r). Cell 75:59-72.
28. Luo J, Manning BD, Cantley LC. 2003. Targeting the PI3K-Akt pathway in human cancer: Rationale and promise. Cancer Cell 4:257-262.
29. Macpherson I, Montagnier L. 1964. Agar suspension culture for the selective assay of cells transformed by polyoma virus. Virology 23:291-294.
30. Morrison KB, Tognon CE, Garnett MJ, Deal C, Sorensen PHB. 2002. ETV6-NTRK3 transformation requires insulin-like growth factor 1 receptor signaling and is associated with constitutive IRS-1 tyrosine phosphorylation. Oncogene 21:5684-5695.
31. Myers MG, Jr., Grammer TC, Wang LM, Sun XJ, Pierce JH, Blenis J, White MF. 1994. Insulin receptor substrate-1 mediates phosphatidykinositol 3′-kinase and p70S6K signaling during insulin, insulin-like growth factor-1 and interleukin-4 stimulation. J Biol Chem 269:28783-28789.
32. Peterson JE, Jelinek T, Kaleko M, Siddle K, Weber MJ. 1994. Phosphorylation and activation of the IGF-1 receptor in src-transformed cells. J Biol Chem 269:27315-27321.
33. Prisco M, Santini F, Baffa R, Liu M, Drakas R, Wu A, Baserga R. 2002. Nuclear translocation of IRS-1 by the SV40 T antigen and the activated IGF-1 receptor. J Biol Chem 277:32078-32085.
34. Ravikumar S, Perez-Liz GH, Del Vale L, Soprano DR, Soprano KJ. 2007. Insulin receptor substrate-1 is an important mediator of ovarian cancer cell growth suppression by all-trans retinoic acid. Cancer Res 67:9266-9275.
35. Reiss K, Valentinis B, Tu X, Xu SQ, Baserga R. 1998. Molecular markers of IGF-1-mediated mitogenesis. Exp Cell Res 242:361-372.
36. Reiss K, Wang JY, Romano G, Tu X, Peruzzi F, Baserga R. 2001. Mechanism of regulation of cell adhesion and motility by insulin receptor substrate-1 in prostate cancer cells. Oncogene 20:490-500.
37. Riedemann J, Maculay VM. 2006. IGF1R signaling and its inhibition. Endocrine-related. Cancer 13:S33-S43.
38. Rocha RL, Hilsenbeck SG, Jackson JG, van der Berg CL, Weng CW, Lee AV, Yee D. 1997. Insulin like growth factor binding protein 3 and insulin receptor substrate-1 in breast cancer: Correlation with clinical parameters and disease-free survival. Clin Cancer Res 3:103-109.
39. Sell C, Rubini M, Rubin R, Liu J-P, Efstratiadis A, Baserga R. 1993. Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type-1 IGF receptor. Proc Natl Acad Sci USA 90:11217-11221.
40. Shi B, Sepp-Lorenzino M, Prisco M, Linsley P, deAngelis T, Baserga R. 2007. Micro RNA 145 targets the insulin receptor substrate-1 and inhibits the growth of colon cancer cells. J Biol Chem in press (available on line).
41. Sun H, Tu X, Prisco M, Wu A, Casiburi I, Baserga R. 2003. Insulin-like growth factor 1 receptor signaling and nuclear translocation of insulin receptor substrates 1 and 2. Mol Endocrinol 17:472-486.
42. Tu X, Batta P, Innocent N, Prisco M, Casaburi I, Belletti B, Baserga R. 2002. Nuclear translocation of insulin receptor substrate-1 by oncogenes and IGF-1: Effect on ribosomal RNA synthesis. J Biol Chem 277:44357-44365.
43. Turkson J, Bowman T, Garcia R, Caldenhoven E, De Groot RP, Jove R. 1998. Stat3 activation by src induces specific gene regulation and is required for cell transformation. Mol Cell Biol 18:2545-2552.
44. Valentinis B, Morrione A, Taylor SJ, Baserga R. 1997. Insulin-like growth factor 1 receptor signaling in transformation by src oncogenes. Mol Cell Biol 17:3744-3754.
45. Valentinis B, Navarro N, Zanocco-Marani T, Edmonds P, McCormick J, Morrione A, Sacchi A, Romano G, Reiss K, Baserga R. 2000. Insulin receptor substrate-1, p70S6K and cell size in transformation and differentiation of hemopoietic cells. J Biol Chem 275:25451-25459.
46. White MF. 1998. The IRS-signalling system: A network of docking proteins that mediate insulin action. Mol Cell Biochem 182:3-11.
47. Wu A, Tu X, Prisco M, Baserga R. 2005. Regulation of Upstream Binding Factor 1 activity by insulin-like growth factor 1 receptor signaling. J Biol Chem 280:2863-2872.
48. Wu A, Chen J, Baserga R. 2007. Nuclear insulin receptor substrate-1 activates promoters of cell cycle progression genes. Oncogene in press, published on line August 13, 2007.
49. Yenush L, Zanella C, Uchida T, Bernal D, White MF. 1998. The pleckstrin homology and phosphotyrosine binding domains of insulin receptor substrate 1 mediate inhibition of apoptosis by insulin. Mol Cell Biol 18:6784-6794.
50. Zong CS, Zong L, Jiang Y, Sadowski HB, Wang LH. 1998. Stat3 plays an important role in oncogenic ros- and insulin-like growth factor 1 receptor-induced anchorage-independent growth. J Biol Chem 273:28065-28072.
51. Zong CS, Chan J, Levy DE, Horvath C, Sadowski HB, Wang LH. 2000. Mechanism of STAT3 activation by insulin-like growth factor 1 receptor. J Biol Chem 275:15099-15105.